United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

UNITED THERAPEUTICS Corp

2025-Q1 EPS reported $6.63 revenue$794,400,000

Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).
Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.
R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.
Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.